WO2009146213A3 - Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction - Google Patents

Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction Download PDF

Info

Publication number
WO2009146213A3
WO2009146213A3 PCT/US2009/041134 US2009041134W WO2009146213A3 WO 2009146213 A3 WO2009146213 A3 WO 2009146213A3 US 2009041134 W US2009041134 W US 2009041134W WO 2009146213 A3 WO2009146213 A3 WO 2009146213A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune tolerance
snp
association
resistance
single nucleotide
Prior art date
Application number
PCT/US2009/041134
Other languages
French (fr)
Other versions
WO2009146213A2 (en
Inventor
Arnold E. Postlethwaite
Weikuan Gu
Original Assignee
The University Of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2010011445A priority Critical patent/MX2010011445A/en
Priority to CA2721651A priority patent/CA2721651A1/en
Priority to BRPI0911104A priority patent/BRPI0911104A2/en
Priority to JP2011505254A priority patent/JP2011520425A/en
Application filed by The University Of Tennessee Research Foundation filed Critical The University Of Tennessee Research Foundation
Priority to EP09755575.9A priority patent/EP2286218B1/en
Priority to EA201001667A priority patent/EA201001667A1/en
Priority to AU2009251508A priority patent/AU2009251508A1/en
Priority to CN2009801231763A priority patent/CN102089655A/en
Priority to US12/988,395 priority patent/US20120135014A1/en
Publication of WO2009146213A2 publication Critical patent/WO2009146213A2/en
Publication of WO2009146213A3 publication Critical patent/WO2009146213A3/en
Priority to IL208777A priority patent/IL208777A0/en
Priority to US14/243,998 priority patent/US20140286971A1/en
Priority to US15/183,764 priority patent/US10450610B2/en
Priority to US16/659,277 priority patent/US20200149108A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy
PCT/US2009/041134 2008-04-18 2009-04-20 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction WO2009146213A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EA201001667A EA201001667A1 (en) 2008-04-18 2009-04-20 ONE-NUCLEOTIC POLYMORPHISMS (SNP) AND CONNECTION WITH RESISTANCE TO THE INDUCTION OF IMMUNOLOGICAL TOLERANCE
BRPI0911104A BRPI0911104A2 (en) 2008-04-18 2009-04-20 single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
JP2011505254A JP2011520425A (en) 2008-04-18 2009-04-20 Association with single nucleotide polymorphism (SNP) and tolerance to induction of immune tolerance
CN2009801231763A CN102089655A (en) 2008-04-18 2009-04-20 Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction
EP09755575.9A EP2286218B1 (en) 2008-04-18 2009-04-20 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
CA2721651A CA2721651A1 (en) 2008-04-18 2009-04-20 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
AU2009251508A AU2009251508A1 (en) 2008-04-18 2009-04-20 Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction
MX2010011445A MX2010011445A (en) 2008-04-18 2009-04-20 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction.
US12/988,395 US20120135014A1 (en) 2008-04-18 2009-04-20 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
IL208777A IL208777A0 (en) 2008-04-18 2010-10-17 Screening methods for susceptibilty to immune tolerance development
US14/243,998 US20140286971A1 (en) 2008-04-18 2014-04-03 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
US15/183,764 US10450610B2 (en) 2008-04-18 2016-06-15 Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction
US16/659,277 US20200149108A1 (en) 2008-04-18 2019-10-21 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7126408P 2008-04-18 2008-04-18
US61/071,264 2008-04-18
US8001208P 2008-07-11 2008-07-11
US61/080,012 2008-07-11
US10450408P 2008-10-10 2008-10-10
US61/104,504 2008-10-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/988,395 A-371-Of-International US20120135014A1 (en) 2008-04-18 2009-04-20 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
US201313972362A Continuation 2008-04-18 2013-08-21

Publications (2)

Publication Number Publication Date
WO2009146213A2 WO2009146213A2 (en) 2009-12-03
WO2009146213A3 true WO2009146213A3 (en) 2010-02-04

Family

ID=41377885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/041134 WO2009146213A2 (en) 2008-04-18 2009-04-20 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction

Country Status (12)

Country Link
US (4) US20120135014A1 (en)
EP (1) EP2286218B1 (en)
JP (1) JP2011520425A (en)
KR (1) KR20110014595A (en)
CN (1) CN102089655A (en)
AU (1) AU2009251508A1 (en)
BR (1) BRPI0911104A2 (en)
CA (1) CA2721651A1 (en)
EA (1) EA201001667A1 (en)
IL (1) IL208777A0 (en)
MX (1) MX2010011445A (en)
WO (1) WO2009146213A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144666A2 (en) * 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
KR102217060B1 (en) * 2019-01-30 2021-02-18 (주)메디젠휴먼케어 Apparatus for analysis and management of individual single nucleotide polymorphism
CN111537315B (en) * 2020-07-13 2020-10-02 天津德祥生物技术有限公司 Erythrocyte membrane separation liquid and erythrocyte membrane separation method
CN114107474A (en) * 2020-08-28 2022-03-01 复旦大学附属华山医院 ANXA6 polymorphic site as gene marker and psoriasis kit combined with methotrexate
CN113215230B (en) * 2021-06-22 2024-02-09 艾康健(武汉)基因技术有限公司 SNP nucleic acid mass spectrometry typing detection method for non-disease diagnosis purpose

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227244A1 (en) * 2002-10-08 2005-10-13 Affymetrix, Inc. Methods for genotyping polymorphisms in humans
US20050244421A1 (en) * 2002-06-13 2005-11-03 Wolfgang Strittmatter Compositions and methods for modulating immune response
US20070172445A1 (en) * 2004-05-27 2007-07-26 Aspid S.S. De C.A. Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone
US20080064668A1 (en) * 2003-09-24 2008-03-13 Bioxell S.P.A. 1,3-Diacylated, 26,27-Alkyl/Haloakyl Vitamin D3 Compounds and Methods of Use Thereof
US20080070253A1 (en) * 2005-01-13 2008-03-20 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
US20080070792A1 (en) * 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
US7811794B2 (en) * 2003-03-18 2010-10-12 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
US20050250125A1 (en) * 2003-12-19 2005-11-10 Novakoff James L Method for conducting pharmacogenomics-based studies
US20060178910A1 (en) * 2005-01-10 2006-08-10 George Eisenberger Publisher gateway systems for collaborative data exchange, collection, monitoring and/or alerting
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244421A1 (en) * 2002-06-13 2005-11-03 Wolfgang Strittmatter Compositions and methods for modulating immune response
US20050227244A1 (en) * 2002-10-08 2005-10-13 Affymetrix, Inc. Methods for genotyping polymorphisms in humans
US20080064668A1 (en) * 2003-09-24 2008-03-13 Bioxell S.P.A. 1,3-Diacylated, 26,27-Alkyl/Haloakyl Vitamin D3 Compounds and Methods of Use Thereof
US20070172445A1 (en) * 2004-05-27 2007-07-26 Aspid S.S. De C.A. Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone
US20080070253A1 (en) * 2005-01-13 2008-03-20 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
US20080070792A1 (en) * 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOOD ET AL.: "Alloantigen-induced specific immunological unresponsiveness", PHILOS. TRANS. R. SOC. LOND. B BIOL. SCI., vol. 356, no. 1409, 2001, pages 665 - 80, XP008146440 *

Also Published As

Publication number Publication date
US10450610B2 (en) 2019-10-22
EA201001667A1 (en) 2011-06-30
BRPI0911104A2 (en) 2015-10-06
CN102089655A (en) 2011-06-08
IL208777A0 (en) 2010-12-30
WO2009146213A2 (en) 2009-12-03
CA2721651A1 (en) 2009-12-03
EP2286218B1 (en) 2016-04-13
EP2286218A4 (en) 2011-12-28
US20170016068A1 (en) 2017-01-19
US20120135014A1 (en) 2012-05-31
MX2010011445A (en) 2011-02-15
US20200149108A1 (en) 2020-05-14
AU2009251508A1 (en) 2009-12-03
JP2011520425A (en) 2011-07-21
EP2286218A2 (en) 2011-02-23
US20140286971A1 (en) 2014-09-25
KR20110014595A (en) 2011-02-11

Similar Documents

Publication Publication Date Title
AU2009303344A8 (en) Targeting of antigen presenting cells with immunonanotherapeutics
WO2009146213A3 (en) Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
WO2012019187A3 (en) Ligation-based detection of genetic variants
BR112013008140A2 (en) "imidazotriazinone compounds".
WO2007098254A3 (en) Nanoparticles for immunotherapy
WO2013150082A8 (en) Hybridization-based replication of nucleic acid molecules
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2013092983A3 (en) Enzymatic conjugation of polypeptides
WO2009105680A3 (en) Genetic polymorphisms associated with stroke, methods of detection and uses thereof
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
WO2010014134A8 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
NZ602220A (en) Antibodies with ph dependent antigen binding
WO2009054996A8 (en) Systems and methods for viral therapy
WO2007095385A3 (en) Technique for providing secure firmware
DK2203439T3 (en) 1 ', 3'-disubstituted 4-phenyl-3,4,5,6-tetrahydro-2H, 1'H- [1,4'] - bipyridinyl-2'-one
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
WO2009055054A3 (en) Antibody-mediated disruption of quorum sensing in bacteria
WO2009055076A3 (en) Methods and compositions for inhibition of immune responses and autoimmunity
WO2012064897A3 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
BR112014008752A2 (en) singular nucleotide polymorphisms useful for predicting the clinical response to glatiramer acetate
NZ592274A (en) Antibodies against interleukin-25
WO2014008312A3 (en) Primers, assays and methods for detecting an e. coli subtype

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980123176.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09755575

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2721651

Country of ref document: CA

Ref document number: 2011505254

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12988395

Country of ref document: US

Ref document number: MX/A/2010/011445

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009251508

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4284/KOLNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107025767

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009755575

Country of ref document: EP

Ref document number: 201001667

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2009251508

Country of ref document: AU

Date of ref document: 20090420

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201013654

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0911104

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101018